Analysis highlights maternal-infant outcomes associated with buprenorphine treatment for opioid use disorder, suggesting effective management of addiction during pregnancy.
(Abstracted from JAMA Health Forum 2025;6(4.11):e251814) Between 1999 and 2017, the number of pregnant people with opioid use disorder (OUD) increased from 1.5 to 8.2 per 1000 delivery hospitalizations in the United States. The American College of Obstetrics and Gynecology and the Substance Abuse and Mental Health Administration endorse the use of either methadone, a full μ-opioid receptor agonist, or buprenorphine, a partial μ-opioid receptor agonist and full κ-receptor antagonist, to treat OUD in pregnancy.
No takes yet. Share an insight, caveat, or question.
Krishnapura et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: